A combined regimen of etretinate and UVB modulate T6+ and HLA-DR+ epidermal cells.
Using anti-T6 and anti-HLA-DR monoclonal antibodies, this study was designed to attain what would do to epidermal Langerhans cell (LC) markers in psoriatic patients when two remedies, etretinate and UVB, having controversial effects on LC were put to use simultaneously. In normal and psoriatic subjects, HLA-DR+ LC was approximately 80% of T6+ LC and a single dose of UVB equivalent to minimal erythema dose (MED), reduced LC membrane markers to approximately 30% of non-irradiated control. The recovery of LC membrane markers, after a single dose of UVB exposure were significantly faster in the group of etretinate treated psoriatic subject than only UVB irradiated psoriatic control. Taken together, seemed to exert prompt recovery of normalization of the number of LC from the depletion following the UVB.
Kim
Y H
YH
Department of Dermatology, Catholic University Medical College, Seoul, Korea.
Kim
C W
CW
Houh
W
W
D000328:Adult; D000911:Antibodies, Monoclonal; D000945:Antigens, Differentiation, T-Lymphocyte / Q000032:analysis; D004359:Drug Therapy, Combination; D005050:Etretinate / Q000627:therapeutic use*; D005260:Female; D006684:HLA-DR Antigens / Q000032:analysis; D006801:Humans; D007150:Immunohistochemistry; D007801:Langerhans Cells / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000473:pathology / Q000628:therapy; D011859:Radiography; D014467:Ultraviolet Therapy
D000911:Antibodies, Monoclonal; D000945:Antigens, Differentiation, T-Lymphocyte; D006684:HLA-DR Antigens; D005050:Etretinate